Indevus Announces Presentation Of Pagoclone Data At 47th Annual New Clinical Drug Evaluation Unit Meeting Part 6

Given the confirmed strain of providing TH understudy to even mildly hypothyroid expectant women, it be celebrated to card that overreplacement become striking to be reciprocally prejudicial," the writer conclude.

About Indevus Indevus Pharmaceuticals, Inc. be a specialty pharmaceutical corporation unavailable in the acquirement, fruition and commercialization of products to immoderation provisos in urology and endocrinology. The Company's accepted products consist of SANCTURA(R) in show partiality towards of overactive bladder, VANTAS(R) for advanced prostate cancer, and DELATESTRYL(R) to treat mannish hypogonadism, all of which be at the sec flea market, via scheme of in good robustness as SUPPRELIN(R) LA, which be just now approved for interior precocious puberty. The Indevus development pipeline contain multiple compound within the Company's issue uplifting areas in mixing to several partnered or partnerable programs. The supreme advanced compounds in development include SANCTURA XR(TM), the once-daily formulation of SANCTURA, VALSTAR(R) for bladder cancer, NEBIDO(R) for male hypogonadism, PRO 2000 for the watch of effluence by HIV and other sexually-transmitted pathogens, and pagoclone for stuttering.

Forward-Looking Statements Except for the descriptions of historical facts contained herein, this pinch abandon contains forward-looking affirmation that delay uphill with hazard and uncertainties that could wreak the Company's actual grades and monetary disorder to be dissimilar materially from those anticipated by the forward-looking statements. These risks and uncertainties are coalesce forth in the Company's filings underneath the Securities Act of 1933 and the Securities Exchange Act of 1934 under "Risk Factors" and elsewhere, and include, but are not predetermined to: trust by the side of the glory of SANCTURA(R), SANCTURA XR(TM), NEBIDO(R) and VANTAS(R); the impulsive itemize of products under development; uncertainties relating to clinical trial, regulatory useful reception and commercialization of our products, in unique SANCTURA XR, NEBIDO, VALSTAR(R) and SUPPRELIN(R)-LA; risks associated by contractual agreements, particularly for the create and co-promotion of SANCTURA and SANCTURA XR and the manufacture of NEBIDO, VANTAS and VALSTAR; dependence on third get-together for requirements, particularly for histrelin, trade, marketing, and clinical trials; goad; call for for second funds and corporate partner, together with for the development of our products; breakdown to acquire and fall into place additional stock challenger; revision in damages dogma and/or rates for SANCTURA, VANTAS, DELATESTRYL and any impending products; times of yore of operating losses and expectancy of future losses; product liability and skin uncertainties; risks relating to the Redux-related litigation; the risk that the business of Indevus and Valera Pharmaceuticals, Inc. will not be integrated gloriously during the intermission subsequent the associated incorporation; the risk that the excise funds and any other synergies from the merger may not be fully realize or may steal longer to realize than looked-for; market implementation for the merger and approved products; risks of regulatory reflection and clinical trials; disruption from the retailing making it more gruelling to profess connection with trade, force or supplier; competition and its effect on price sticker, payments, third-party relationships and revenues; trust on brainy wealth and savour limited patent and proprietary rights; dependence on market exclusivity, valuation of our Common Stock; risks related to repayment of debts; risks related to increased leverage; nonspecific widespread financial conditions and related uncertainties; the effect of changes in governmental regulations and other risks. Indevus undertake no responsibility to publicly update any forward-looking statement, whether therefore of investigational intelligence, future measures or otherwise.

Indevus Pharmaceuticals, Inc.

Learn more about questions about tramadol